Funding for this research was provided by:
Natural Science Foundation of Shanghai (19ZR1411200)
Program of Shanghai Academic Research Leader (KW1428)
China Anti-Cancer Association (SACA-AX201904)
Received: 1 December 2020
Accepted: 28 March 2021
First Online: 8 April 2021
: All in vivo animal experiments were performed in compliance with the <i>NIH Guide for the Care and Use of Laboratory Animal</i>s (ExternalRef removed) and were approved by the Fudan Animal Ethics Committee. All surgical procedures were.conducted under anaesthesia to minimise animal suffering.
: All authors agree to the publication of our work titled “Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer” to <i>Journal of Experimental & Clinical Cancer Research</i>.
: The authors have declared that no competing interest exists.